Evidence map›Paper›PMID 33005806›Full record

ArticleHeliyon2020

Optimized platelet rich plasma releasate (O-rPRP) repairs galactosemia-induced ovarian follicular loss in rats by activating mTOR signaling and inhibiting apoptosis.

Wesam El Bakly, Marwa Medhat, Mohamed Shafei, Reham Tash, Mohamed Elrefai, Yousef Shoukry, Nesreen Nabil Omar

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Selected Genetic Factors Associated with Primary Ovarian Insufficiency.International journal of molecular sciences · 2023
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Wesam El BaklyDepartment of Pharmacology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Marwa MedhatDepartment of Pharmacology, National Center for Social & Criminological Research, Egypt.
Mohamed ShafeiObstetrician and Gynecologist at Sidnawy Health Insurance Hospital, Cairo, Egypt.
Reham TashDepartment of Anatomy and Embryology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mohamed ElrefaiDepartment of Anatomy and Embryology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Yousef ShoukryDepartment of Anatomy and Embryology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Nesreen Nabil OmarDepartment of Biochemistry, Faculty of Pharmacy, Modern University for Technology and Information, 11 Saudia Buildings, Nozha Street, 11371, Cairo, Egypt.
Ain Shams University · EGAl-Ahram Center for Political and Strategic Studies · EGHashemite University · JOKing Abdulaziz University · SAModern University for Information and Technology · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelet rich plasma contains a collection of growth factors, and an optimal formulation, named O-rPRP, contains the highest possible concentration of growth factors. PURPOSE: Challenging the healing power of O-rPRP in a high-galactose diet-induced premature ovarian insufficiency (POI) experimental rat model.

methodsRats were divided into four groups of ten rats each and treated for four week as follows; 1) the control group, fed with normal diet and received intraperitoneal (i.p.) injection of PBS once/week; 2) the POI group, fed with galactose diet (50%) and received PBS (i.p.) once/week; 3) the POI/O-rPRP group, fed a 50% galactose diet and received O-rPRP (i.p.) once/week; 4) the O-rPRP group (negative control), fed with a normal diet and received O-rPRP (i.p.) once/week. The levels of galactose, follicle stimulating hormone, 17 β-estradiol, anti-mullerian hormone and inhibin B were measured in serum samples. Western blotting and quantitative real-time PCR assays were employed to investigate the levels of miR-223, β1 integrin, p70S6k and MCL-1 in ovarian tissues.

resultsAfter O-rPRP treatment, β1 integrin expression was enhanced, and miR-223 expression was decreased. Unlike the untreated galactose group, in the group treated with O-rPRP, p70S6k and MCL-1 expression levels were increased, indicating that the mTOR growth signaling pathway was active and that apoptosis was inactive. After the introduction of O-rPRP, the number of follicles and the follicular maturation improved, which was consistent with the improvement of inhibin B levels and subsequent inhibition of FSH.

conclusionO-rPRP inhibited galactose-induced excessive atresia and provided an overall protective effect on the ovarian follicles.

Indexed as

Alternative medicineApoptosisCell biologyGalactosemiamTOROvarian insufficiencyPlatelet rich plasmaRegenerative medicineReproductive hormoneReproductive systemToxicology

Identifiers

PMID33005806
PMCPMC7509792
OpenAlexW3087872381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.